CADL Stock Forecast: Candel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.04
−1.75% on the day

The median 12-month analyst price target for Candel Therapeutics, Inc. is $18. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$402.4M
Ticker Nerd rank
43/ 100
Median analyst target
$18
Analysts covering
10
Revenue$0.0
Operating income−$26.7M
Net income−$38.9M
Free cash flow−$17.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.7%
1M
−41.7%
YTD
−10.8%
1Y
+14.0%
From 52W high
−63.3%
From 52W low
+14.0%
$4
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Candel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
43/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
68
Accruals
66
Momentum
65
Quality
60
Volatility
52
Revisions
50
Growth
16
Issuance
6

Value (68): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CADL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CADL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26CADLHigh $29Median $18Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10
Buy
0
Hold
0
Sell
$11
Low
$18
Median
$29
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
16 Nov 2026CitigroupMaintainsBuy$26 → $20
13 Nov 2026Canaccord GenuityMaintainsBuy$25 → $13
13 Nov 2026HC Wainwright & Co.MaintainsBuy$23 → $18
13 Nov 2026StifelMaintainsBuy$22 → $19
22 Oct 2026JefferiesInitiatesBuy$25
21 Sept 2026B of A SecuritiesUpgradeBuy$12 → $18
14 Aug 2026B of A SecuritiesMaintainsNeutral$9.00 → $12
13 Aug 2026HC Wainwright & Co.ReiteratesBuy$23
13 July 2026StifelInitiatesBuy$22
20 Apr 2026Cantor FitzgeraldInitiatesOverweight—
18 Mar 2026CitigroupMaintainsBuy—
13 Mar 2026Canaccord GenuityMaintainsBuy—
13 Mar 2026CitigroupMaintainsBuy—
8 Dec 2025Stephens & Co.ReiteratesOverweight—
21 Nov 2025Freedom BrokerMaintainsBuy—
14 Nov 2025CitigroupMaintainsBuy—
28 Oct 2025Stephens & Co.InitiatesOverweight—
21 Oct 2025LifeSci CapitalInitiatesOutperform—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025B of A SecuritiesDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CADL.

Market Radar

This page is one stock. Monday covers all of them.

CADL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CADL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Candel Therapeutics, Inc. returned +14.0% against +6.9% for the S&P 500, dividends included.

CADL vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26CADLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CADL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.0×

Cheaper than 31% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−93.6%

Higher than 14% of US stocks

Return on assets
−33.5%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Candel Therapeutics, Inc. has a market value of $402.4M and an enterprise value of $249.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$88.5M.

  • Diluted earnings per share, trailing twelve months: −$1.41.

  • Free cash flow in the twelve months to 30 June 2026: −$57.3M.

  • Shares outstanding: 76.1M.

  • Candel Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CADL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CADLCandel Therapeutics, Inc.$402.4M43
AVTXAvalo Therapeutics, Inc.$390.9M29
TVGNTevogen, Inc.$405.2M17
IRDOpus Genetics, Inc.$385.7M39
OVIDOvid Therapeutics, Inc.$410.6M47
CRMDCorMedix, Inc.$410.8M63
TECXTectonic Therapeutic, Inc.$413.5M44

Take a look at CADL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Candel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CADL

What is the CADL stock price forecast for 2026-2027?

The median 12-month analyst price target for Candel Therapeutics, Inc. is $18, with estimates ranging from $11 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CADL stock a buy right now?

Of the 10 analysts covering Candel Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Candel Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CADL?

As at 21 Nov 2026, Candel Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (68 of 100).

Will CADL stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $18, and Ticker Nerd's factor model ranks Candel Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CADL stock forecast for 2030?

No analyst covering Candel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CADL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $29 over the next 12 months.

How has CADL stock performed over the past year?

Candel Therapeutics, Inc. returned +14.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Candel Therapeutics, Inc. do?

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors.

Company

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. · 55 employees · United States · https://www.candeltx.com